Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.55
-0.27 (-0.54%)
Streaming Delayed Price
Updated: 3:50 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Could Novavax Become the Next Moderna?
Today 5:40 EDT
Sanofi believes in Novavax's vaccine strengths...
Via
The Motley Fool
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...
Via
Benzinga
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
May 15, 2024
Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas.
Via
Benzinga
3 Stocks Under $2 That Can Trade in Double Digits by 2025
May 15, 2024
These stocks under $2 are likely to surge higher as they represent companies with impending growth catalysts.
Via
InvestorPlace
Novavax Stock Just Tripled. Is It Too Late to Buy?
May 15, 2024
Novavax shares have soared and plummeted in recent years.
Via
The Motley Fool
Why Novavax Stock More Than Doubled Today
May 10, 2024
A cloud of doubt hanging over the company just gave way to some sunshine.
Via
The Motley Fool
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
May 14, 2024
Via
Benzinga
3 Cheap Biotech Stocks to Buy Now: May 2024
May 14, 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.
Via
InvestorPlace
Exposures
Product Safety
3 Meme Stocks That Are Likely to Crater in 2024
May 14, 2024
These are the meme stocks to avoid as they represent fundamentally weak companies with a sluggish growth outlook.
Via
InvestorPlace
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
May 13, 2024
Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 13, 2024
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
NVAX Stock Alert: Novavax Just Hit a New 52-Week High
May 10, 2024
Novavax stock is heading higher on Friday as NVAX investors celebrate it reaching a new 52-week high following a deal with Sanofi.
Via
InvestorPlace
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
May 10, 2024
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novavax Sheds Going Concern Warning as NVAX Stock Pops on Sanofi Licensing Deal
May 10, 2024
NVAX stock is rising higher after the biotechnology company announced that it had signed a licensing deal with Sanofi.
Via
InvestorPlace
Biotech Rockets 125% On Sanofi Covid Vaccine Agreement
May 10, 2024
Novavax will receive as much as $1.2 billion as part of a Covid vaccine licensing deal with Sanofi.
Via
Investor's Business Daily
Exposures
COVID-19
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern
May 10, 2024
Novavax strikes co-exclusive licensing deal with Sanofi (SNY) for COVID-19 and flu-COVID-19 vaccines. Terms include upfront payment of $500M, milestone opportunities, and revenue guidance update.
Via
Benzinga
Exposures
COVID-19
Why Is Novavax (NVAX) Stock Up 118% Today?
May 10, 2024
Novavax stock is up on Friday after the vaccine company announced a licensing agreement with Sanofi as its Q1 earnings report.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 10, 2024
The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning!
Via
InvestorPlace
3 Biotech Stocks to Sell in May Before They Crash & Burn
May 10, 2024
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.
Via
InvestorPlace
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
May 09, 2024
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.
Via
InvestorPlace
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
May 08, 2024
Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Sanofi's New Cancer Drug Could Help Deliver a Big Payday
May 08, 2024
Investors should expect a modest 2024 before seeing more exciting returns for the drugmaker in 2025 following the expected approval of rilzabrutinib.
Via
The Motley Fool
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
May 02, 2024
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.
Via
Benzinga
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 02, 2024
It pays to develop novel medicines for life-threatening illnesses.
Via
The Motley Fool
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
April 28, 2024
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for...
Via
Talk Markets
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
April 25, 2024
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
Via
Benzinga
Sanofi (SNY) Q1 2024 Earnings Call Transcript
April 25, 2024
SNY earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
April 25, 2024
Via
Benzinga
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
April 25, 2024
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.